Back to today’s briefing

Story perspectives

Transcarent Acquires Accolade for $621 Million, Boosting Healthcare Access

1/9/2025

28 4

Summary

Story summary

Transcarent is acquiring Accolade for $621 million, offering $7.03 per share, a 110% premium.
The merger, set to finalize in Q2 2025, will combine Transcarent's AI services with Accolade's platform.
Both boards have unanimously approved the deal, transitioning Accolade to a private company.
This merger aims to enhance healthcare access and lower costs for employers and consumers.

1 of 1

Story summary

Transcarent is acquiring Accolade for $621 million, offering $7.03 per share, a 110% premium.
The merger, set to finalize in Q2 2025, will combine Transcarent's AI services with Accolade's platform.
Both boards have unanimously approved the deal, transitioning Accolade to a private company.
This merger aims to enhance healthcare access and lower costs for employers and consumers.